Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

Table 2 Treatments and outcomes

No.	Initial dose of regorafenib (mg)	Dose adjustment (mg)	PD-1 inhibitor used in combination	Number of treatment cycles	Best response	PFS (mo)	OS (mo)
1	120		Camrelizumab	16	SD	11.2	12.0
2	80		Tislelizumab	7	SD	5.0	7.0
3	160	160→80	Nivolumab	4	PD	3.4	Not reached
4	80		Camrelizumab	4	PD	3.4	4.0
5	80		Tislelizumab	3	SD	2.0	5.0
6	80		Toripalimab	5	SD	3.5	Not reached
7	80		Tislelizumab	7	SD	5.0	9.0
8	80		Pembrolizumab	5	PD	3.5	Not reached
9	120		Sintilimab	4	SD	2.8	Not reached
10	160	160→80	Toripalimab	8	SD	5.6	Not reached
11	80		Tislelizumab	2	SD	1.4	Not reached
12	160		Toripalimab	4	SD	2.8	Not reached
13	120		Nivolumab	6	SD	4.2	Not reached
14	80		Toripalimab	5	SD	3.5	Not reached
15	120		Sintilimab	6	SD	3.5	Not reached
16	80		Nivolumab	15	SD	10.5	Not reached
17	160	160→80	Sintilimab	4	PD	2.8	Not reached
18	80		Camrelizumab	5	PD	3.5	Not reached
19	80		Toripalimab	2	SD	1.4	Not reached
20	120		Camrelizumab	4	PD	3.4	7.0
21	80		Toripalimab	2	PD	1.4	Not reached
22	120		Camrelizumab	1	SD	0.7	12.0
23	80		Sintilimab	2	PD	1.4	10.0
24	80		Toripalimab	9	SD	6.3	11.0
25	120	120→80	Sintilimab	2	PD	1.4	Not reached
26	80		Sintilimab	3	SD	2.1	10.0
27	80		Toripalimab	6	SD	4.2	Not reached
28	120		Sintilimab	2	PD	1.4	Not reached
29	80		Sintilimab	1	PD	0.7	not reached
30	80		Sintilimab	2	PD	1.4	Not reached

OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; SD: Stable disease; PD-1: Programmed cell death-1.